We are developing the leading protein-protein interaction drug discovery platform.

Protein-protein interaction (PPI) drug discovery is bottlenecked by poor-quality PPI assays. Industry standard assays detect only 10% to 20% of true positive PPIs. That leaves most targets and hit compounds in the dark.

We aim to change that.